Dimitris Hatzibougias

Dr. Dimitris Hatzibougias

Aristotle University, Thessaloníki, Kentrikí Makedonía, Greece
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2007 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
GFGeorgios Fyrmpas
Georgios Fyrmpas
IKI. Konstantinidis
I. Konstantinidis
DHDimitris Hatzibougias
Dimitris Hatzibougias
VVV. Vital
V. Vital
JCJ. Constantinidis
J. Constantinidis

29 December 2008 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
DHDimitris Hatzibougias
Dimitris Hatzibougias
MBMattheos Bobos
Mattheos Bobos
GKGeorgia Karayannopoulou
Georgia Karayannopoulou
GKGeorgios Karkavelas
Georgios Karkavelas
GKGeorgios T Karapanagiotidis
Georgios T Karapanagiotidis
IKIoannis Kostopoulos
Ioannis Kostopoulos
Background: Coexistence of adenocarcinoma and mantle cell lymphoma in the same or different anatomical sites is extremely rare. We present a case of incidental discovery of primary lung adenocarcinoma and mantle cell lymphoma involving the pleura, during an axillary thoracotomy performed for a benign condition. Case presentation: A 73-year old male underwent bullectomy and apical pleurectomy for persistent pneumothorax. A bulla of the lung apex was resected en bloc with a scar-like lesion of the lung, which was located in proximity with the bulla origin, by a wide wedge resection. Histologic examination of the stripped-off parietal pleura and of the bullectomy specimen revealed the synchronous occurrence of two distinct neoplasms, a lymphoma infiltrating the pleura and a primary, early lung adenocarcinoma. Immunohistochemical and fluorescence in situ hybridization assays were performed. The morphologic, immunophenotypic and genetic findings supported the diagnosis of primary lung adenocarcinoma (papillary subtype) coexisting with a non-Hodgkin, B-cell lineage, mantle cell lymphoma involving both, visceral and parietal pleura and without mediastinal lymph node involvement. The neoplastic lymphoid cells showed the characteristic immunophenotype of mantle cell lymphoma and the translocation t(11;14). The patient received 6 cycles of chemotherapy, while pulmonary function tests precluded further pulmonary parenchyma resection (lobectomy) for his adenocarcinoma. The patient is alive and without clinical and radiological findings of local recurrence or distant relapse from both tumors 14 months later. Conclusion: This is the first reported case of a rare tumoral combination involving simultaneously lung and pleura, emphasizing at the incidental discovery of the two coexisting neoplasms during a procedure performed for a benign condition. Any tissue specimen resected during operations performed for non-tumoral conditions should be routinely sent for pathologic examination.

3 May 2012 in Journal of Neurological Surgery Part A: Central European Neurosurgery
Verified
Journal Article
Closed access
PDF file
MPM. Potsi
M. Potsi
PSP. Stavrinou
P. Stavrinou
NPN. Patsinakidis
N. Patsinakidis
DHDimitris Hatzibougias
Dimitris Hatzibougias
NFN. Foroglou
N. Foroglou
AKA. Kalogera-Founzila
A. Kalogera-Founzila
Primary osseous leiomyosarcoma of the spine is an extremely rare entity with only 13 previous cases having been reported in the literature. We present the case of a 57-year-old woman with a tumor of the eleventh thoracic vertebra, causing compression of the spinal cord. Histopathology and immunohistochemical results of the tumor biopsy specimen disclosed a primary leiomyosarcoma of the thoracic spine. We report on the features of this rare entity but also review and summarize the imaging and pathology characteristics that can be extrapolated from the existing literature. * This article was originally published online in Central European Neurosurgery on July 27, 2010 (DOI:10.1055/s-0030-1253409)

1 January 2017 in Respiratory Medicine Case Reports
Verified
Journal Article
Open access
Paul ZarogoulidisPaul Zarogoulidis
Paul Zarogoulidis
EAEvaggelia Athanasiou
Evaggelia Athanasiou
TTTheodora Tsiouda
Theodora Tsiouda
DHDimitris Hatzibougias
Dimitris Hatzibougias
HHHaidong Huang
Haidong Huang
WHWolfgang Hohenforst-Schmidt
Wolfgang Hohenforst-Schmidt
In this decade a "bloom" of novel therapies has been observed for non-small cell lung cancer. We have new tools for the diagnosis of lung cancer and also we can re-biospy easier than before in different lesions and obtain tissue samples in order to investigate whether a patient can receive new targeted therapies. Immunotherapy has been well established previously for other forms of cancer, and nowadays it is also available for lung cancer. There are two immunotherapies for now nivolumab and pembrolizumab which can be administered as second line treatment, the second can also be administered as first-line if there is a programmed death-ligand 1 ≥50% expression.

Paul ZarogoulidisPaul Zarogoulidis
Paul Zarogoulidis
CKChristoforos S. Kosmidis
Christoforos S. Kosmidis
Wolfgang Hohenforst-SchmidtWolfgang Hohenforst-Schmidt
Wolfgang Hohenforst-Schmidt
Dimitrios MatthaiosDimitrios Matthaios
Dimitrios Matthaios
KSKonstantinos Sapalidis
Konstantinos Sapalidis
JTJ. Francis Turner
J. Francis Turner
Introduction: Diagnosis of lung nodules is still under investigation. We use computed tomography scans and positron emission tomography in order to identify their origin. Patients and Methods: In our retrospective study, we included 248 patients with a single lung nodule or multiple lung nodules of size ≥1 cm. We used a radial-endobronchial ultrasound and a C-Arm. We used a 1.1 mm cryoprobe versus a 22G needle vs. forceps/brush. We compared the sample size of each biopsy method with the number of cell-block slices. Results: Central lesions indifferent to the method provided the same mean number of cell-block slices (0.04933–0.02410). Cryobiopsies provide less sample size for peripheral lesions due to the higher incidence of pneumothorax (0.04700–0.02296). Conclusion: The larger the lesion ≥2 cm, and central, more cell-blocks are produced indifferent to the biopsy method (0.13386–0.02939). The time of the procedure was observed to be less when the C-Arm was used as an additional navigation tool (0.14854–0.00089).

22 May 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
EFElena Fountzilas
Elena Fountzilas
TPTheofanis Papadopoulos
Theofanis Papadopoulos
EPEirini Papadopoulou
Eirini Papadopoulou
CGCedric Gouedard
Cedric Gouedard
HKHelen (Eleni) Kourea
Helen (Eleni) Kourea
Zenia SaridakiZenia Saridaki
Zenia Saridaki
Determination of microsatellite instability (MSI)/mismatch repair (MMR) status in cancer has several clinical implications. Our aim was to integrate MSI/MMR status from patients tested in Greece to assess the prevalence of MSI-high (MSI-H)/deficient MMR (dMMR) per tumor type, testing patterns over time and concordance between MSI and MMR status. We retrospectively recorded MSI/MMR testing data of patients with diverse tumor types performed in pathology and molecular diagnostics laboratories across Greece. Overall, 18 of 22 pathology and/or molecular diagnostics laboratories accepted our invitation to participate. In the 18 laboratories located across the country, 7916 tumor samples were evaluated for MSI/MMR status. MSI/MMR testing significantly increased in patients with colorectal cancer (CRC) and other tumor types overtime (p < 0.05). The highest prevalence was reported in endometrial cancer (47 of 225 patients, 20.9%). MSI-H/dMMR was observed in most tumor types, even in low proportions. Among 904 tumors assessed both for MSI and MMR status, 21 had discordant results (overall discordance rate, 2.3%). We reported MSI-H/dMMR prevalence rates in patients with diverse cancers, while demonstrating increasing referral patterns from medical oncologists in the country overtime. The anticipated high rate of concordance between MSI and MMR status in paired analysis was confirmed.